Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

103.09 -0.79 (-0.76%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

60 61 Next >

BioNTech Jumps On Surprise Profit, Wide Sales Beat; But Lowers Outlook ↗

November 04, 2024

The company now expects sales to come in at the lower end of its previous guidance.

Via Investor's Business Daily

As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗

November 01, 2024

Amid the election, and a Fed rate vote, earnings season roars ahead.

Via Investor's Business Daily

Topics Economy Stocks

Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? ↗

October 24, 2024

This drugmaker's lead candidate could become a top-selling cancer therapy.

Via The Motley Fool

FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment ↗

October 21, 2024

BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current participants continue treatment, and other trials remain unaffected.

Via Benzinga

Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology ↗

October 17, 2024

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines.

Via Benzinga

Topics Lawsuit

Forecasting The Future: 15 Analyst Projections For BioNTech ↗

October 07, 2024

Via Benzinga

Forecasting The Future: 8 Analyst Projections For BioNTech ↗

September 13, 2024

Via Benzinga

GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement ↗

October 15, 2024

GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine...

Via Benzinga

Topics Intellectual Property Lawsuit

Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake ↗

October 07, 2024

Shares peaked near 62 in late 2021, but are now worth less than half of that.

Via Investor's Business Daily

Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 07, 2024

Via Benzinga

Consumer Tech News (Sept 30-Oct 4): Latest Windows 11 Update Causing Trouble, Apple Accused Of Compelling Employees To Sign Illegal Agreements & More ↗

October 06, 2024

Major tech companies lobby against CA bill regulating AI, Apple faces legal complaints, iPhone users retain devices longer. Google warns Apple app removal.

Via Benzinga

Topics Artificial Intelligence Law Enforcement

Market Whales and Their Recent Bets on BNTX Options ↗

September 13, 2024

Via Benzinga

Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research ↗

October 02, 2024

This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research.

Via Benzinga

Topics Artificial Intelligence

Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 24, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Via Benzinga

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗

September 17, 2024

BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.

Via Investor's Business Daily

Here's Why Everyone's Talking About Summit Therapeutics ↗

September 17, 2024

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

Via The Motley Fool

DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions ↗

September 16, 2024

Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and...

Via Benzinga

Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio? ↗

September 15, 2024

These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.

Via Benzinga

Should You Buy Novavax Stock After This Regulatory Win? ↗

September 13, 2024

The biotech continues to earn important wins, but is it enough?

Via The Motley Fool

GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech ↗

September 11, 2024

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...

Via Benzinga

Why Is Moderna Stock Trading Higher On Monday? ↗

September 09, 2024

Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu...

Via Benzinga

Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows ↗

September 06, 2024

Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys.

Via Benzinga

UK, Taiwan Approve Moderna's Updated COVID-19 Shot ↗

September 03, 2024

The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for...

Via Benzinga

Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million ↗

August 31, 2024

UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and...

Via Talk Markets

Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales ↗

August 29, 2024

BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and...

Via Benzinga

Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program ↗

August 26, 2024

US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season.

Via Benzinga

FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot ↗

August 22, 2024

The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to...

Via Benzinga

FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch ↗

August 19, 2024

The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.

Via Benzinga

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.